Emergent BioSolutions (NYSE:EBS) Rating Increased to Buy at StockNews.com

StockNews.com upgraded shares of Emergent BioSolutions (NYSE:EBS) from a hold rating to a buy rating in a report issued on Monday morning.

Other analysts have also issued reports about the stock. Benchmark lifted their price target on shares of Emergent BioSolutions from $8.00 to $12.00 and gave the stock a “buy” rating in a research note on Thursday, November 7th. HC Wainwright reaffirmed a “buy” rating and issued a $15.00 target price on shares of Emergent BioSolutions in a research report on Tuesday, January 21st.

Emergent BioSolutions Price Performance

NYSE EBS opened at $7.95 on Monday. Emergent BioSolutions has a one year low of $1.48 and a one year high of $15.10. The stock has a 50-day moving average of $9.69 and a 200 day moving average of $9.10. The company has a debt-to-equity ratio of 1.30, a quick ratio of 1.47 and a current ratio of 2.88. The company has a market capitalization of $430.89 million, a price-to-earnings ratio of -1.94 and a beta of 1.62.

Institutional Investors Weigh In On Emergent BioSolutions

Large investors have recently made changes to their positions in the company. State Street Corp lifted its stake in shares of Emergent BioSolutions by 864.7% in the 3rd quarter. State Street Corp now owns 1,911,327 shares of the biopharmaceutical company’s stock worth $15,960,000 after purchasing an additional 1,713,200 shares during the period. Oak Hill Advisors LP purchased a new stake in Emergent BioSolutions during the third quarter valued at approximately $9,296,000. Millennium Management LLC raised its position in Emergent BioSolutions by 83.0% in the fourth quarter. Millennium Management LLC now owns 1,481,906 shares of the biopharmaceutical company’s stock worth $14,167,000 after acquiring an additional 671,947 shares during the period. Invesco Ltd. raised its position in Emergent BioSolutions by 70.9% in the fourth quarter. Invesco Ltd. now owns 1,539,907 shares of the biopharmaceutical company’s stock worth $14,722,000 after acquiring an additional 638,995 shares during the period. Finally, Dimensional Fund Advisors LP boosted its stake in shares of Emergent BioSolutions by 67.5% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,104,058 shares of the biopharmaceutical company’s stock worth $10,554,000 after acquiring an additional 444,790 shares during the last quarter. 78.40% of the stock is currently owned by institutional investors.

Emergent BioSolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.